Sestrin2 Contributes to BRAF Inhibitor Resistance Via Reducing Redox Vulnerability of Melanoma Cells

Treatment resistance often occurs with BRAF inhibitor (BRAFi) therapy for melanoma, bringing in a great challenge to the treatment of melanoma patients harboring mutant BRAF gene. Recent studies revealed redox vulnerability constitutes a novel opportunity to overcome BRAFi resistance. Previously we found Sestrin2 provided protection to metastatic melanoma cells by detoxifying reactive oxygen species (ROS) induced by anoikis, but its defensive role against redox stimuli elicited by BRAFi was unclear.
Source: Journal of Dermatological Science - Category: Dermatology Authors: Source Type: research